Frontlight ResearchEarly access
Chronic myeloid leukaemia trials in United States
84 of 100 trials · From ClinicalTrials.gov, checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 2Taking peopleCladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
- Where
- Houston
- Age
- 18 years to 65 years
- People
- 508
- Run by
- M.D. Anderson Cancer Center
See details and how to joinNCT02115295 - Phase 1Taking peopleAllogeneic iNKT Cell Therapy (agenT-797) After SCT
- Where
- Madison
- Age
- 18 years and over
- People
- 22
- Run by
- University of Wisconsin, Madison
See details and how to joinNCT07758218 - Phase 2Taking peopleBlinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia
- Where
- Houston
- Age
- 18 years and over
- People
- 90
- Run by
- M.D. Anderson Cancer Center
See details and how to joinNCT03263572 - Phase 2Taking peopleDexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers
- Where
- Houston
- Age
- 12 years and over
- People
- 100
- Run by
- M.D. Anderson Cancer Center
See details and how to joinNCT03589729 - Phase 2Taking peopleStudy to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
- Where
- Chicago, Cincinnati, New Brunswick, New York, Seattle
- Age
- 1 year to 18 years
- People
- 50 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07354074 - Phase 4Taking peopleAsciminib Roll-over Study
- Where
- Ann Arbor, Cincinnati, Dallas, Houston, Milwaukee, New York, Portland, Salt Lake City, St Louis
- Age
- 7 years to 100 years
- People
- 347 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT04877522 · EU 2023-507557-16-00 - Phase 1/2Taking peopleAxatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia
- Where
- Columbus, Portland
- Age
- 18 years and over
- People
- 49
- Run by
- Uma Borate
See details and how to joinNCT06523556 - Phase 2Not yet taking people in United StatesRopeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia
- Where
- Los Angeles
- Age
- 18 years and over
- People
- 35
- Run by
- Jonsson Comprehensive Cancer Center
See details and how to joinNCT07468916 - Phase 2Taking peoplePersonalized NK Cell Therapy in CBT
- Where
- Houston
- Age
- 15 years to 80 years
- People
- 100
- Run by
- M.D. Anderson Cancer Center
See details and how to joinNCT02727803 - Phase 2Taking peoplePhase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.
- Where
- Houston
- Age
- 18 years and over
- People
- 150
- Run by
- M.D. Anderson Cancer Center
See details and how to joinNCT06236724 - Phase 2Taking peoplePhase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia
- Where
- Houston
- Age
- 18 years and over
- People
- 40
- Run by
- M.D. Anderson Cancer Center
See details and how to joinNCT06629584 - Phase 1Taking peopleAutologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
- Where
- Bethesda
- Age
- 18 years to 120 years
- People
- 86
- Run by
- National Cancer Institute (NCI)
See details and how to joinNCT06904066 - Phase 1/2Not yet taking people in United StatesPhase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML
- Where
- Houston
- Age
- 18 years to 70 years
- People
- 30
- Run by
- M.D. Anderson Cancer Center
See details and how to joinNCT07604233 - Phase 1Not yet taking people in United StatesMaintenance Treatment With Imetelstat in Patients With High-Risk Myeloid Neoplasms After Allo-SCT
- Where
- Madison
- Age
- 18 years to 80 years
- People
- 27
- Run by
- University of Wisconsin, Madison
See details and how to joinNCT07909733 - Phase 1/2Taking peoplePhase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)
- Where
- Gainesville, Miami, St. Petersburg
- Age
- Up to 50 years
- People
- 40
- Run by
- University of Florida
See details and how to joinNCT05322850 - Phase 1Taking peopleProphylactic DLI-X for Leukemia Relapse After HCT
- Where
- Tucson
- Age
- Up to 65 years
- People
- 180
- Run by
- University of Arizona
See details and how to joinNCT07254793 - Phase 2Taking peopleCord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
- Where
- Seattle
- Age
- 6 months to 65 years
- People
- 54
- Run by
- Fred Hutchinson Cancer Center
See details and how to joinNCT06013423 - Phase 2Taking peopleCMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
- Where
- Atlanta, Boston, Duarte
- Age
- 18 years to 75 years
- People
- 216
- Run by
- City of Hope Medical Center
See details and how to joinNCT06059391 - Phase 1Taking peopleA Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
- Where
- Atlanta, Boston, Duarte
- Age
- 18 years to 75 years
- People
- 46
- Run by
- City of Hope Medical Center
See details and how to joinNCT07020533 - Phase 1Taking peopleTherapeutic RSK1 Targeting in Myeloid Malignancies
- Where
- St Louis
- Age
- 18 years and over
- People
- 30
- Run by
- Washington University School of Medicine
See details and how to joinNCT07379125 - Phase 1Taking peopleTGRX-678 US Phase I for Chronic Myelogenous Leukemia Patients
- Where
- Houston, Seattle
- Age
- 18 years and over
- People
- 90
- Run by
- Shenzhen TargetRx Co., Ltd.
See details and how to joinNCT06088888 - Phase 1Taking peopleOlutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant
- Where
- Cleveland, Duarte
- Age
- 18 years and over
- People
- 15
- Run by
- City of Hope Medical Center
See details and how to joinNCT06543381 - Phase 1/2Taking peopleA Clinical Study of MK-4208/TERN-701 in Participants With Chronic Myeloid Leukemia (CML) (MK-4208-003/Tern701-1012/CARDINAL)
- Where
- Augusta, Birmingham, Eugene, Fort Myers, Gilbert, Houston, Lone Tree, Nashville, New York, Ocala, Orange, Philadelphia, Portland, Salt Lake City, Seattle, St. Petersburg, West Palm Beach, Winston-Salem
- Age
- 18 years to 64 years
- People
- 330 worldwide
- Run by
- Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
See details and how to joinNCT06163430 · EU 2023-507677-18-00 - Phase 2Taking peopleEffects of IL-1 Beta Inhibition on Vascular Inflammation in TET2 Clonal Hematopoiesis
- Where
- Boston
- Age
- 18 years and over
- People
- 120
- Run by
- Massachusetts General Hospital
See details and how to joinNCT06691217 - Phase 2Taking peoplePhase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
- Where
- Houston
- Age
- 18 years and over
- People
- 40
- Run by
- M.D. Anderson Cancer Center
See details and how to joinNCT07269470